Update shared on 20 Nov 2025
Fair value Increased 11%Analysts have increased their price target for Prothena, raising it from $16.50 to $18.33. They cite optimism about the company's partnered pipeline and upcoming catalysts as key drivers for this upward revision.
Analyst Commentary
Bullish analysts have raised price targets for Prothena, highlighting several positive aspects of the company’s outlook.
Bullish Takeaways- The partnered pipeline is viewed as a major strength, offering attractive long-term revenue potential from royalties and milestone payments.
- Upcoming catalysts over the next year and beyond are expected to drive meaningful value creation for shareholders.
- There is an expectation of substantial upside, given the company’s positioning within high-growth therapeutic areas and strong partnerships.
- Optimism around execution and delivery on pipeline milestones supports an increased valuation outlook.
- Analysts remain cautious about the company’s ability to consistently deliver on key pipeline milestones, which could impact future valuation if delayed.
- Potential risks include reliance on partnered programs and external milestone achievements, which may introduce uncertainty into revenue projections.
- Market competition in the relevant therapeutic segments could temper long-term growth if Prothena faces setbacks in product differentiation or commercialization.
What's in the News
- Publication of Phase 2 clinical trial data for coramitug (formerly PRX004) in ATTR amyloidosis with cardiomyopathy, including presentation at the American Heart Association's Scientific Sessions and publication in Circulation. Novo Nordisk has initiated the Phase 3 CLEOPATTRA trial, and Prothena is eligible for up to $1.2 billion in milestone payments (Key Developments).
- Prothena released results from the Phase 1 ASCENT clinical program for PRX012 in early symptomatic Alzheimer's disease, demonstrating meaningful reductions in amyloid plaque and outlining future partnership opportunities for further development (Key Developments).
- A Special/Extraordinary Shareholders Meeting is scheduled for November 19, 2025, in Dublin to consider a reduction in company capital to facilitate the creation of distributable reserves (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased from $16.50 to $18.33. This reflects greater confidence in Prothena's future prospects.
- Discount Rate has risen slightly from 7.24% to 7.39%. This indicates a marginally higher perceived risk or required return.
- Revenue Growth projection has fallen significantly, declining from 89.76% to 74.72%.
- Net Profit Margin estimate has improved modestly, moving from 16.28% to 16.98%.
- Future P/E has expanded from 93.77x to 112.74x. This suggests a higher valuation relative to anticipated future earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.